Cellenkos, Inc. Announces FDA Registration of GMP Manufacturing Facility

February 6th 2018

HOUSTON, Feb. 6, 2018 /PRNewswire/ -- Cellenkos, Inc., a clinical-stage biotechnology company focused on developing universal donor cell therapeutics derived from cord blood (CB) for the treatment of autoimmune diseases and inflammatory conditions, today announced the successful registration of its stand-alone, manufacturing facility as GMP (good manufacturing practice) compliant with U.S. Food and Drug Administration (FDA).